1.2500
07-October-24 14:59:55
15 minutes delayed
Stocks
-0.0100
-0.79%
Today's range
1.2000 - 1.3100
ISIN
N/A
Source
NASDAQ
Inhibikase Therapeutics to Report Second Quarter Financial Results on November 14, 2023
07 Nov 2023 07:00:01 By Nasdaq GlobeNewswire
Inhibikase Therapeutics Highlights Unblinded Functional Analysis from the 201 Trial of Risvodetinib in Untreated Parkinson’s Disease and Provides Update on Ongoing Enrollment
16 Oct 2023 06:00:27 By Nasdaq GlobeNewswire
Inhibikase Therapeutics Receives FDA Orphan Drug Designation for Risvodetinib for the Treatment of Multiple System Atrophy
04 Oct 2023 07:30:00 By Nasdaq GlobeNewswire